Overview: NGS Tuberous Sclerosis Sequencing TestIntroduction: The NGS Tuberous Sclerosis Sequencing Test sequences genes to diagnose tuberous sclerosis, causing tumors or seizures. Aligned with 2023 AAN guidelines, it uses PCR for high specificity, supporting neurological screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in molecular pathology for patients with suspected tuberous sclerosis complex (TSC).
Other Names: Tuberous Sclerosis NGS Assay, TSC1/TSC2 Gene Test.
FDA Status: Laboratory-developed test (LDT), meeting molecular pathology standards for diagnostic accuracy.
Historical Milestone: Tuberous sclerosis sequencing began in the 1990s with TSC research. NGS methods improved in the 2010s, enhancing diagnostic precision.
Purpose: Sequences genes to diagnose tuberous sclerosis, guides treatment, and evaluates patients with tumors or seizures.
Test Parameters: 1. Tuberous Sclerosis Genes
Pretest Condition: No fasting required. Collect whole blood, buccal swab, or saliva. Report history of seizures, tumors, or TSC symptoms.
Specimen: Whole Blood (EDTA, 2-5 mL), Buccal Swab (sterile swab, 1-2 swabs), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not frozen
Medical History: Document seizures, tumors, skin lesions, or family history of TSC. Include current medications, especially anticonvulsants or mTOR inhibitors.
Consent: Written consent required, detailing the tests purpose, TSC implications, and risks of sample collection.
Procedural Considerations: Uses next-generation sequencing to analyze TSC genes (e.g., TSC1, TSC2). Results are available in 3-5 days, supporting clinical decisions. Performed in laboratories, often for TSC diagnosis.
Factors Affecting Result Accuracy: Low DNA yield or improper sample storage can affect results. Contamination may reduce specificity.
Clinical Significance: Identified mutations confirm TSC, guiding mTOR inhibitor therapy or genetic counseling. Negative results may require imaging studies.
Specialist Consultation: Consult a neurologist or geneticist for result interpretation and treatment planning.
Additional Supporting Tests: Brain MRI, EEG, or renal imaging to confirm TSC diagnosis.
Test Limitations: Not all TSC cases are genetic; clinical correlation is needed. Sample quality affects sensitivity.
References: AAN TSC Guidelines, 2023; Neurology, Northrup H, 2022.
